Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)

癌症研究和管理信息学技术的先进发展(U24临床试验可选)

基本信息

  • 批准号:
    10217061
  • 负责人:
  • 金额:
    $ 75.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-15 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

In the past two decades, we have taken large strides towards understanding the role of the microbiota (the trillions of microorganisms inhabiting the human body) and the microbiome (their genes) in human health. Individual microbial or viral pathogens are implicated in the etiology of many cancers, including gastric, colon, and cervical cancer. Still more cancers likely arise from the interplay of many different microbial taxa, their metabolic activities, the host’s genotype and immune system activity, and factors such as host diet, current and former smoking status, and environmental exposures. We propose to advance cancer microbiome research through three specific aims. This work will be performed in the context of the popular QIIME 2 microbiome bioinformatics platform and the Qiita public microbiome data repository and pooled analysis system. In our first aim, we will improve access to cancer microbiome bioinformatics methods and data through the creation of a Galaxy interface for QIIME 2, improved support for working with QIIME 2 in the R programming language and Galaxy GUI ecosystem, popular for cancer research, the development of a resource for cancer microbiome pooled analysis, the development of a cancer- focused microbiome bioinformatics workshop series, and by making QIIME 2 and cancer microbiome data accessible from within the NCI Cloud Resources. Our second aim will develop a microbiome multi-omics bioinformatics platform driven by the needs of the cancer research community through creating QIIME 2 plugins for metabolomics, metatranscriptomics, metagenomics, and metaproteomics with developers working in these areas. Many important cancer microbiome projects have made advances by integrating these different data types, yet considerable technical hurdles remain to making microbiome multi-omics bioinformatics accessible by all researchers whose projects would benefit from these methods. To facilitate this, we will create a microbiome multi-omics bioinformatics developer conference, following the model of our recent Teaching and Developing QIIME 2 conference. Our third aim will improve the reproducibility of cancer microbiome bioinformatics methods, and the reliability of cancer microbiome bioinformatics results, by expanding several features related to tracking data provenance in QIIME 2, and helping users submit their microbiome multi-omics raw data to archival repositories. Much of this work will occur in collaboration with NCI Informatics Technology for Cancer Research (ITCR) and Cloud Resources project teams, several of whom we’re already beginning to collaborate with.
在过去的二十年里,我们在理解微生物群的作用方面取得了很大的进步

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James Gregory Caporaso其他文献

James Gregory Caporaso的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James Gregory Caporaso', 18)}}的其他基金

Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
癌症研究和管理信息学技术的先进发展(U24临床试验可选)
  • 批准号:
    10665002
  • 财政年份:
    2020
  • 资助金额:
    $ 75.25万
  • 项目类别:
Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
癌症研究和管理信息学技术的先进发展(U24临床试验可选)
  • 批准号:
    10447021
  • 财政年份:
    2020
  • 资助金额:
    $ 75.25万
  • 项目类别:
Determining the Role of the Upper and Lower Airway Microbiota as Drivers of Concomitant Inflammatory Responses in patients with Chronic Rhinosinusitis and Asthma
确定上呼吸道和下呼吸道微生物群作为慢性鼻窦炎和哮喘患者伴随炎症反应驱动因素的作用
  • 批准号:
    9813180
  • 财政年份:
    2019
  • 资助金额:
    $ 75.25万
  • 项目类别:
Project 1: Viewing Native American Cervical Cancer Disparities through the Lens of the Vaginal Microbiome
项目 1:通过阴道微生物组观察美洲原住民宫颈癌的差异
  • 批准号:
    10251192
  • 财政年份:
    2009
  • 资助金额:
    $ 75.25万
  • 项目类别:
Project 1: Viewing Native American Cervical Cancer Disparities through the Lens of the Vaginal Microbiome
项目 1:通过阴道微生物组观察美洲原住民宫颈癌的差异
  • 批准号:
    10021586
  • 财政年份:
    2009
  • 资助金额:
    $ 75.25万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 75.25万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 75.25万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 75.25万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 75.25万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 75.25万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 75.25万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 75.25万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 75.25万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 75.25万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 75.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了